Polymyxin B for Injection 500,000 IU (50 mg) Suppliers & Bulk Manufacturers
Available Forms: Lyophilised powder vial (IV, IM, intrathecal)
Available Strengths: 500,000 IU (50 mg)
Pack Sizes: Single vial, packs of 10
Originator reference: (brand names belong to their owners and are shown only to identify the originator medicine)
Category: Antibiotics
Polymyxin B 500,000 IU injection is a last-line antibiotic for multidrug-resistant Gram-negative infections such as carbapenem-resistant Acinetobacter, Pseudomonas and Klebsiella. PharmaTradz connects hospital, tender and distributor buyers with GMP-certified manufacturers and licensed exporters, and checks the documents needed for the destination market.
Manufacture or export Polymyxin B for Injection? List it or send an offer →
Product Description:
Polymyxin B is a polypeptide antibiotic that binds the outer membrane of Gram-negative bacteria and breaks it open. It is closely related to colistin (polymyxin E), but it is given in its active form rather than as a prodrug, so blood levels are reached faster and are more predictable. For that reason many intensive care units prefer it for bloodstream and lung infections caused by carbapenem-resistant organisms.
It is used for serious infections caused by multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae, often in combination with another antibiotic. Kidney function and nerve side effects need close monitoring. Each vial contains 500,000 international units, equal to 50 mg of polymyxin B.
Sourcing notes. Demand rises sharply where carbapenem resistance is common, including South and South-East Asia, Latin America, the Middle East and Eastern Europe. Hospital tenders usually ask for USP or EP compliance, potency data and stability for the local climate. Colistin injection and nebuliser solution are also listed on PharmaTradz.
Handling, dosing and buyer checklist
Storage and preparation. Unopened vials are usually kept refrigerated at 2–8°C. The powder is reconstituted with sterile water or sodium chloride 0.9% and, for intravenous use, diluted further and infused slowly. Strength is expressed in units: 1 mg of polymyxin B equals 10,000 units, so a 500,000-unit vial contains 50 mg.
How it is given. International guidance for carbapenem-resistant infections recommends a weight-based loading dose followed by maintenance doses every 12 hours, without the usual cut in dose for kidney function that applies to colistin. Kidney function and signs of nerve toxicity are monitored throughout treatment. Doses are always set by the treating team.
What to ask a supplier. Potency per vial in units and the pharmacopoeia standard (USP or EP), certificate of analysis with bacterial endotoxin results, remaining shelf life at dispatch (vials typically carry 24–36 months), cold-chain arrangements, and registration status in the destination country or eligibility for import under a shortage or special-access route.
Polymyxin B for Injection — third party manufacturing & bulk supply
Polymyxin B for Injection 500,000 IU (50 mg) is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
Indicative minimum order quantity
Polymyxin B for Injection is supplied as Lyophilised powder vial (IV, IM, intrathecal) — supplied in more than one dosage form, each with its own manufacturing economics, so the indicative MOQ is a minimum order value of USD 5,000 per product. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.
Manufacturers of Polymyxin B for Injection listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.
Request a quote for Polymyxin B for Injection →Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.
Frequently Asked Questions
Serious infections caused by multidrug-resistant Gram-negative bacteria, such as carbapenem-resistant Acinetobacter, Pseudomonas and Klebsiella.
Both are polymyxins. Polymyxin B is given in its active form, while colistin is given as a prodrug that converts in the body, so polymyxin B reaches effective levels more quickly.
500,000 IU (50 mg) per vial, as a powder for reconstitution.
Yes. Share the quantity, pharmacopoeia standard and destination, and we match you with GMP manufacturers holding the needed registrations.
Related Products
Ceftazidime + Avibactam for Injection
Strength:
2 g + 0.5 g
Form: Powder for concentrate vial (IV infusion)
Originator reference: Zavicefta, Avycaz
View DetailsCeftolozane + Tazobactam for Injection
Strength:
1 g + 0.5 g
Form: Powder for concentrate vial (IV infusion)
Originator reference: Zerbaxa (MSD)
View DetailsMeropenem + Vaborbactam for Injection
Strength:
1 g + 1 g
Form: Powder for concentrate vial (IV infusion)
Originator reference: Vabomere (US), Vaborem (EU)
View DetailsDelamanid Tablets
Strength:
50 mg; 25 mg dispersible (paediatric)
Form: Film-coated tablets, dispersible tablets
Originator reference: Deltyba (Otsuka)
View DetailsNitazoxanide / Ofloxacin
Strength:
125mg+50mg
Form: Oral suspension
Originator reference: -
View DetailsOfloxacin / Ornidazole Tablets
Strength:
200mg+ 500mg
Form: Tablets
Originator reference: -
View DetailsSpiramycin Tablets
Strength:
3 MIU, 1.5MIU
Form: Tablets
Originator reference: Rovamycine (EU/UK)
View DetailsUsually answered within 48 hours | GMP documents shared before you commit